The appropriateness of PSMA PET/CT in newly diagnosed unfavorable intermediate-risk prostate cancer patients-towards a tumor volume-based risk stratification

被引：1

作者：

Hagens, Marinus J. ^{[1
,2
,3
]}

Luining, Wietske I. ^{[2
,3
]}

Boeve, Liselotte M. S. ^{[4
]}

Knol, Remco J. J. ^{[5
]}

Roeleveld, Ton A. ^{[3
,6
]}

Srbljin, Sandra ^{[7
]}

Weltings, Saskia ^{[8
]}

Koppes, Jose C. C. ^{[9
]}

Oprea-Lager, Daniela E. ^{[9
]}

Vis, Andre N. ^{[2
,3
]}

van Leeuwen, Pim J. ^{[1
,3
]}

van der Poel, Henk G. ^{[1
,2
,3
]}

机构：

[1] Antoni Van Leeuwenhoek Hosp NCI AVL, Netherlands Canc Inst, Dept Urol, Amsterdam, Netherlands

[2] Univ Amsterdam, Locat VUMC, Dept Urol, Med Ctr, Amsterdam, Netherlands

[3] Prostate Canc Network Netherlands, Amsterdam, Netherlands

[4] OLVG, Dept Urol, Amsterdam, Netherlands

[5] Noordwest Ziekenhuisgroep, Dept Nucl Med, Alkmaar, Netherlands

[6] Noordwest Ziekenhuisgroep, Dept Urol, Alkmaar, Netherlands

[7] Zaans Med Ctr, Dept Nucl Med, Zaandam, Netherlands

[8] Zaans Med Ctr, Dept Urol, Zaandam, Netherlands

[9] Univ Amsterdam, Dept Radiol & Nucl Med, Locat VUmc, Med Ctr, Amsterdam, Netherlands

来源：

PROSTATE CANCER AND PROSTATIC DISEASES | 2024年

关键词：

MEN;

D O I：

10.1038/s41391-024-00899-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/objectives: This study reassesses the diagnostic value of PSMA PET/CT in unfavorable intermediate-risk prostate cancer (PCa) and validates the Prostate Cancer Network the Netherlands (PCNN) subclassification. Subjects/methods: Men subjected to PSMA PET/CT were analyzed, evaluating the incidence of metastatic disease and its correlation with PCNN subgroups. Results: Metastatic disease was identified in 12.4% of patients. Higher PCNN subgroups correlated with increased metastatic potential; odds were significantly lower in low metastatic potential cases (OR: 0.19, 95% CI 0.06-0.62; p = 0.01). Conclusions: Our findings reaffirm PSMA PET/CT's diagnostic value in unfavorable intermediate-risk PCa and validate the PCNN subclassification, reducing scan burden by 48.1%.

引用

页数：3

共 50 条

[1] The Diagnostic Value of PSMA PET/CT in Men with Newly Diagnosed Unfavorable Intermediate-Risk Prostate Cancer
Hagens, Marinus J.
Luining, Wietske I.
Jager, Auke
Donswijk, Maarten L.
Cheung, Zing
Wondergem, Maurits
Oprea-Lager, Daniela E.
Vis, Andre N.
van Leeuwen, Pim J.
van der Poel, Henk G.
JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (08) : 1238 - 1243
[2] Importance of prostate volume in the stratification of patients with intermediate-risk prostate cancer
Moschini, Marco
Gandaglia, Giorgio
Suardi, Nazareno
Fossati, Nicola
Cucchiara, Vito
Damiano, Rocco
Cantiello, Francesco
Shariat, Shahrokh F.
Montorsi, Francesco
Briganti, Alberto
INTERNATIONAL JOURNAL OF UROLOGY, 2015, 22 (06) : 555 - 561
[3] Stratification of patients with intermediate-risk prostate cancer
Jung, Jin-Woo
Lee, Jung Keun
Hong, Sung Kyu
Byun, Seok-Soo
Lee, Sang Eun
BJU INTERNATIONAL, 2015, 115 (06) : 907 - 912
[4] PSMA PET/CT in the low- to intermediate-risk prostate cancer: when and why?
Sofia, Luca
Bauckneht, Matteo
ASIAN JOURNAL OF ANDROLOGY, 2024, 26 (06): : 584 - 586
[5] Current insights on PSMA PET/CT in intermediate-risk prostate cancer: a literature review
Guglielmo, Priscilla
Buffi, Nicolo
Porreca, Angelo
Setti, Lucia
Arico, Demetrio
Muraglia, Lorenzo
Evangelista, Laura
ANNALS OF NUCLEAR MEDICINE, 2025, 39 (03) : 247 - 254
[6] Editorial Comment to Importance of prostate volume in the stratification of patients with intermediate-risk prostate cancer
Yashi, Masahiro
INTERNATIONAL JOURNAL OF UROLOGY, 2015, 22 (06) : 561 - 562
[7] PSMA PET/CT and Magnetic Resonsance Imaging Features in Patients with Favorable and Unfavorable Intermediate Risk Prostate Cancer
Guglielmo, P.
Muraglia, L.
Jandric, J.
Giacoppo, G.
Bambaci, M.
Bonacina, M.
Zanca, R.
Lughezzani, G.
Buffi, N.
Fasulo, V.
Setti, L.
Marzo, K.
Rodari, M.
Arico, D.
Evangelista, L.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S527 - S527
[8] Improving the Stratification of Patients With Intermediate-risk Prostate Cancer
Stolzenbach, Lara Franziska
Nocera, Luigi
Colla-Ruvolo, Claudia
Tian, Zhe
Knipper, Sophie
Maurer, Tobias
Tilki, Derya
Graefen, Markus
Karakiewicz, Pierre I.
CLINICAL GENITOURINARY CANCER, 2021, 19 (02) : E120 - E128
[9] THE DIAGNOSTIC VALUE OF PSMA PET/CT IN MEN WITH NEWLY DIAGNOSED INTERNATIONAL SOCIETY OF UROLOGICAL PATHOLOGY GRADE GROUP 3 INTERMEDIATE-RISK PROSTATE CANCER
Hagens, Marinus J.
Luining, Wietske I.
Jager, Auke
Wondergem, Maurits
Donswijk, Maarten L.
Cheung, Zing
Oprea-Lager, Daniela E.
Vis, Andre N.
van Leeuwen, Pim J.
van der Poel, Henk G.
JOURNAL OF UROLOGY, 2023, 209 : E550 - E551
[10] Stratification of brachytherapy-treated intermediate-risk prostate cancer patients into favorable and unfavorable cohorts
Merrick, Gregory S.
Butler, Wayne M.
Galbreath, Robert W.
Fiano, Ryan
Adamovich, Edward
JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2015, 7 (06) : 430 - 436

← 1 2 3 4 5 →